Bayer Says BlueRock Therapeutics Closes First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

Donnerstag, 06.01.2022 14:10 von PLX

• (PLX AI) – Bayer says BlueRock Therapeutics announces closeout of first cohort in Phase 1 Trial in patients with Advanced Parkinson’s Disease.
• • BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease
• • The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with Parkinson’s disease
• • Enrollment of the first cohort of patients was completed at three active sites in the United States and Canada: Weill Cornell Medicine, University of California, Irvine and University Health Network
• • Patients in the first cohort received a bilateral surgery to transplant dopaminergic neurons in the midbrain region
• • No severe adverse events were observed in any participating patients